Replication-selective viruses for cancer therapy

Journal of Molecular Medicine

Volumn 80, Issue 3, 2002, Pages 163-175

  Biederer, Carola ^a   Ries, Stefan ^b   Brandts, Christian H ^c   McCormick, Frank ^c  

^a SWITCH Biotech AG   (Germany)

^b MediGene AG   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer therapy; ONYX 015; Replication selective viruses; Tumor; clinical trials

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CV 706; CV 787; G 207; ONCOLYTIC VIRUS; ONYX 015; RECOMBINANT DNA; UNCLASSIFIED DRUG;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTECHNOLOGY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CELL KILLING; DRUG DOSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; GENE MUTATION; GENETIC ENGINEERING; HEAD AND NECK CANCER; HUMAN; MONOTHERAPY; NONHUMAN; RECURRENT CANCER; TISSUE CULTURE; TUMOR CELL; VIRUS CELL INTERACTION; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CELL CYCLE; CLINICAL TRIALS; GENETIC VECTORS; HUMANS; NEOPLASMS; REOVIRIDAE; SIMPLEXVIRUS; VIRUS REPLICATION;

EID: 0036118404     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-001-0295-1     Document Type: Article

References (113)

1. The current status of gene therapy
2. Strategies for manipulating the p53 pathway in the treatment of human cancer
3. A novel MDM 2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer
4. Viral gene delivery
5. Construction of retroviral vectors for targeted delivery and expression of therapeutic genes
6. Virus vector design in gene therapy
7. Viruses in the treatment of cancer
8. Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses
9. Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First clinical results with tumor-cell vaccines modified with live but avirulent Newcastle disease virus
10. Factors influencing the interferon response
11. Newcastle disease virus as an antineoplastic agent: Induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity
12. Reovirus therapy of tumors with activated Ras pathway
13. Newcastle disease virus selectively kills human tumor cells
14. The hallmarks of cancer
15. Molecular dissection of multi-stage tumorigenesis in transgenic mice
16. The multistep nature of cancer
17. Exploiting the p53 pathway for cancer diagnosis and therapy
18. The p53 tumour suppressor gene
19. The p53 tumour suppressor gene
20. Cancer cell cycles
21. Retinoblastoma protein switches the E2F site from positive to negative element
22. G1 phase progression: Cycling on cue
23. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
24. The regulation of E2F by pRB-family proteins
25. The complexity of p53 modulation: Emerging patterns from divergent signals
26. p53, the cellular gatekeeper for growth and division
27. Dial 9-1-1 for p53: Mechanisms of p53 activation by cellular stress
28. How to activate p53
29. Mdm2 promotes the rapid degradation of p53
30. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
31. WAF1, a potential mediator of p53 tumor suppression
32. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
33. p19ARF links the tumour suppressor p53 to Ras
34. p14ARF links the tumour suppressors RB and p53
35. The ARF/p53 pathway
36. P19 (ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2
37. Association of p19 (ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
38. The tumor suppressor protein p16INK4a
39. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
40. The retinoblastoma protein and cell cycle control
41. The role of RB in cell cycle control
42. p53 mutations in human cancers
43. Database of p53 gene somatic mutations in human tumors and cell lines: Updated compilation and future prospects
44. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas
45. Amplification and overexpression of the MDM 2 gene in a subset of human malignant gliomas without p53 mutations
46. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma
47. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence
48. Viral transactivating proteins
49. Regulation of the cell cycle by viral onco-proteins
50. E1A signaling to p53 involves the p19 (ARF) tumor suppressor
51. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55 K proteins
52. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein
53. Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53
54. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins
55. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B
56. Oncogenic potential of the adenovirus E4orf6 protein
57. Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells
58. Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff
59. Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport
60. T antigen is bound to a host protein in SV40-transformed cells
61. Characterization of a 54 K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells
62. Viruses in human cancers
63. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I
64. Epstein-Barr virus-increasing evidence of a link to carcinoma
65. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
66. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
67. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and anti-tumoral efficacy that can be augmented by standard chemotherapeutic agents
68. p53-independent and -dependent requirements for E1B-55 k in adenovirus type 5 replication
69. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection
70. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status
71. Replication of ONYX-015, a potential anti-cancer adenovirus, is independent of p53 status in tumor cells
72. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015)
73. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
74. Regulation of TNF-mediated cell death and inflammation by human adenoviruses
75. In vivo tumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
76. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
77. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial
78. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer
79. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
80. Safety and feasibility of injection with an E1B-55 kDa gene-deleted replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial
81. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity
82. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
83. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
84. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
85. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts
86. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy
87. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression
88. Viral vectors for gene therapy
89. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma
90. Biochemical characteristics and clinical applications of alpha-fetoprotein isoforms
91. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
92. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery
93. Experimental therapy of human glioma by means of a genetically engineered virus mutant
94. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture
95. ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures
96. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant
97. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells
98. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
99. Prodrug-activating systems in suicide gene therapy
100. Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer
101. Replication-selective microbiological agents: Fighting cancer with targeted germ warfare
102. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase
103. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
104. The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus
105. Ras oncogenes in human cancer: A review
106. Regulation of Ras signal transduction in normal and transformed cells
107. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy
108. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy
109. Differential regulation of lipopolysaccharide-induced interleukin 1 and tumor necrosis factor synthesis: Effects of endogenous and exogenous glucocorticoids and the role of the pituitary-adrenal axis
110. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses
111. Conditionally replicating herpes vectors for cancer therapy
112. Viruses as antitumor weapons
113. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions